Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Cartesian Therapeutics (RNAC) Income from Continuing Operations (2016 - 2026)

Cartesian Therapeutics (RNAC) has disclosed Income from Continuing Operations for 12 consecutive years, with 25473000.0 as the latest value for Q1 2026.

  • For Q1 2026, Income from Continuing Operations fell 28.17% year-over-year to 25473000.0; the TTM value through Mar 2026 reached 142425000.0, down 222.22%, while the annual FY2025 figure was 130302000.0, 68.27% down from the prior year.
  • Income from Continuing Operations hit 25473000.0 in Q1 2026 for Cartesian Therapeutics, up from 77371000.0 in the prior quarter.
  • Across five years, Income from Continuing Operations topped out at 14952000.0 in Q2 2024 and bottomed at 196658000.0 in Q4 2023.
  • Average Income from Continuing Operations over 5 years is 24640647.06, with a median of 17858000.0 recorded in 2023.
  • Year-over-year, Income from Continuing Operations soared 5505.67% in 2022 and then tumbled 3437.15% in 2023.
  • Cartesian Therapeutics' Income from Continuing Operations stood at 5893000.0 in 2022, then crashed by 3437.15% to 196658000.0 in 2023, then soared by 87.66% to 24277000.0 in 2024, then plummeted by 218.7% to 77371000.0 in 2025, then surged by 67.08% to 25473000.0 in 2026.
  • According to Business Quant data, Income from Continuing Operations over the past three periods came in at 25473000.0, 77371000.0, and 19518000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.